60 Degrees Pharmaceuticals (SXTP) Income Statement

60 Degrees Pharmaceuticals reported revenue of $1.01M in fiscal 2025 (fiscal year ended Mar 31, 2026), up 47.6% from $681.35K a year earlier. 60 Degrees Pharmaceuticals posted a net loss of $7.37M, compared with a net loss of $8.43M a year earlier. Gross margin was 22.3% and operating margin -771.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $207.90K, down 32.5% from the same quarter a year earlier.

60 Degrees Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

60 Degrees Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Mar 2026	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	1.01	1.41	0.68	0.25	0.51	6.35	2.55
Cost of Revenue	0.78	2.89	5.37	0.47	0.96	6.36	1.51
Gross Profit	0.22	0.63	0.30	-0.22	0.08	5.50	1.04
Operating Expenses
Research & Development	2.11	2.11	4.99	0.69	0.53	5.51	0.81
Selling, General & Administrative	6.28	6.28	5.03	4.24	1.30	1.12	1.46
Operating Expenses	7.98	8.39	10.01	4.93	1.83	6.63	1.46
Operating Income	-7.76	-7.76	-9.72	-5.15	-1.75	-1.12	-0.42
Other Income/Expense
Interest Income	0.00	-	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.01	0.01	-0.01	2.29	-3.99	-3.17	-2.63
Other Income/Expense	0.39	0.39	1.76	1.34	-4.43	-3.14	-2.63
Income
Income Before Tax	-7.37	-7.37	-7.96	-3.81	-6.18	-4.26	-3.05
Income Tax Expense	0.00	-	0.00	0.00	0.00	0.00	0.00
Net Income	-7.37	-7.86	-8.43	-3.77	-6.18	-4.27	-3.03
Net Income - Continuous Operations	-7.37	-7.37	-7.95	-3.77	-6.18	-4.25	-3.03
Net Income - Discontinued Operations	-	-	-	-	-	-	-
EBITDA	-7.28	-7.68	-9.66	-1.43	-1.72	-1.09	-0.39
EBIT	-	-7.76	-9.72	-5.15	-1.75	-1.12	-0.42
Depreciation & Amortization	0.08	0.08	0.05	0.10	0.03	0.03	0.03
Earnings Per Share
Basic EPS	-12.00	-12.00	-74.00	-4.00	-52.00	-	-2.00
Diluted EPS	-12.00	-12.00	-74.00	-4.00	-52.00	-242.00	-2.00
Basic Shares Outstanding	0.67	0.67	0.11	0.02	0.03	18.86	0.02
Diluted Shares Outstanding	0.67	0.67	0.11	0.02	0.03	18.86	0.02

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About 60 Degrees Pharmaceuticals Financial Statements

What was 60 Degrees Pharmaceuticals's revenue in fiscal 2025?

60 Degrees Pharmaceuticals reported revenue of $1.01M in fiscal 2025 (fiscal year ended Mar 31, 2026). That was up 47.6% from $681.35K a year earlier.

Is 60 Degrees Pharmaceuticals profitable?

No. 60 Degrees Pharmaceuticals reported a net loss of $7.37M in fiscal 2025. In fiscal 2024 it lost $8.43M.

What is 60 Degrees Pharmaceuticals's operating margin?

60 Degrees Pharmaceuticals's operating income was −$7.76M on revenue of $1.01M in fiscal 2025, an operating margin of -771.6%, compared with -1425.9% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition